Hong Kong Stock Market Anomalies | Koji Pharmaceutical-B (02171.HK) up over 7% Kakdon passed the preliminary form review of the 2026 commercial insurance innovative drug catalog.

According to the Securities Times APP, Sino Biopharmaceutical Limited (02171.HK) rose over 7%, as of the time of publication, it increased by 6.7% to 17.05 Hong Kong dollars, with a turnover of 46,393.34 million Hong Kong dollars.